THC · Tenet Healthcare Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $21.31B | $20.66B | $20.55B | $19.17B | $19.48B | $17.64B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $863.00M | $818.00M | $870.00M | $841.00M | $855.00M | $857.00M |
| Operating Income | $3.51B | $5.96B | $2.51B | $2.33B | $2.87B | $1.99B |
| Interest Expense | $821.00M | $826.00M | $901.00M | $890.00M | $923.00M | $1.00B |
| Income Tax | $433.00M | $1.18B | $306.00M | $344.00M | $411.00M | ($97.00M) |
| Net Income | $2.37B | $4.06B | $1.31B | $1.00B | $1.48B | $399.00M |
| EPS - Basic | $15.61 | $33.02 | $6.01 | $3.84 | $8.55 | $3.80 |
| EPS - Diluted | $15.49 | $32.70 | $5.71 | $3.79 | $8.42 | $3.75 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.88B | $3.02B | $1.23B | $858.00M | $2.36B | $2.45B |
| Accounts Receivable | $2.56B | $2.54B | $2.91B | $2.94B | $2.77B | $2.69B |
| Inventory | $348.00M | $346.00M | $411.00M | $405.00M | $384.00M | $368.00M |
| Accounts Payable | $1.36B | $1.29B | $1.41B | $1.50B | $1.30B | $1.21B |
| Current Assets | $7.85B | $7.68B | $7.17B | $5.98B | $7.08B | $7.15B |
| Total Assets | $29.68B | $28.94B | $28.31B | $27.16B | $27.58B | $27.11B |
| Current Liabilities | $4.46B | $4.31B | $4.76B | $4.48B | $5.11B | $4.85B |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $20.70B | $20.39B | $22.80B | $22.55B | $23.32B | $24.22B |
| Stockholders' Equity | $4.22B | $4.17B | $1.61B | $1.14B | $1.03B | $28.00M |
| Retained Earnings | $4.42B | $3.01B | ($192.00M) | ($803.00M) | ($1.21B) | ($2.13B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.54B | $2.05B | $2.37B | $1.08B | $1.57B | $3.41B |
| Investing Cash Flow | ($1.27B) | $3.43B | ($969.00M) | ($808.00M) | ($714.00M) | ($1.61B) |
| Financing Cash Flow | ($2.40B) | ($3.69B) | ($1.03B) | ($1.78B) | ($936.00M) | $385.00M |
| CapEx | $1.01B | $931.00M | $751.00M | $762.00M | $658.00M | $540.00M |
| Free Cash Flow | $2.53B | $1.12B | $1.62B | $321.00M | $910.00M | $2.87B |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 16.5% | 28.8% | 12.2% | 12.2% | 14.7% | 11.3% |
| EBITDA margin | 20.5% | 32.8% | 16.4% | 16.6% | 19.1% | 16.1% |
| Net margin | 11.1% | 19.7% | 6.4% | 5.2% | 7.6% | 2.3% |
| Free cash flow margin | 11.9% | 5.4% | 7.9% | 1.7% | 4.7% | 16.3% |
| FCF / Net income | 1.07 | 0.27 | 1.24 | 0.32 | 0.62 | 7.19 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | 15.5% | 22.6% | 18.9% | 25.6% | 21.8% | -32.1% |
| Return on assets | 8.0% | 14.0% | 4.6% | 3.7% | 5.4% | 1.5% |
| Return on equity | 56.1% | 97.4% | 81.5% | 87.7% | 143.6% | 1425.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.76 | 1.78 | 1.51 | 1.34 | 1.38 | 1.47 |
| Quick ratio | 1.68 | 1.70 | 1.42 | 1.25 | 1.31 | 1.40 |
| Cash ratio | 0.65 | 0.70 | 0.26 | 0.19 | 0.46 | 0.50 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 4.3x | 7.2x | 2.8x | 2.6x | 3.1x | 2.0x |
| Equity multiplier | 7.03 | 6.94 | 17.61 | 23.78 | 26.83 | 968.07 |
| Liabilities / Assets | 0.70 | 0.70 | 0.81 | 0.83 | 0.85 | 0.89 |
| Efficiency | ||||||
| Asset turnover | 0.72 | 0.71 | 0.73 | 0.71 | 0.71 | 0.65 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 44d | 45d | 52d | 56d | 52d | 56d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 12.8x | 3.9x | 13.2x | 12.9x | 9.7x | 10.6x |
| P / B | 4.3x | 3.0x | 4.9x | 4.7x | 8.6x | 151.5x |
| P / S | 0.8x | 0.6x | 0.4x | 0.3x | 0.5x | 0.2x |
| EV / EBITDA | 3.5x | 1.4x | 2.0x | 1.4x | 1.7x | 0.6x |
| Growth | ||||||
| Revenue growth (YoY) | 3.1% | 0.6% | 7.2% | -1.6% | 10.5% | -4.5% |
| Revenue CAGR (3y) | 3.6% | 2.0% | 5.2% | 1.2% | -2.6% | - |
| Revenue CAGR (5y) | 3.9% | 2.3% | -0.5% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -41.1% | 137.3% | 7.6% | -18.7% | 44.3% | 31.5% |
| Net income growth (YoY) | -41.8% | 210.0% | 31.0% | -32.2% | 269.9% | - |
| EPS growth (YoY) | -52.6% | 472.7% | 50.7% | -55.0% | 124.5% | - |
| EPS CAGR (3y) | 59.9% | 57.2% | 15.0% | - | 98.9% | - |
| EPS CAGR (5y) | 32.8% | - | 39.8% | - | - | - |
| FCF growth (YoY) | 126.7% | -31.2% | 405.6% | -64.7% | -68.3% | 409.2% |
| FCF CAGR (5y) | -2.5% | 14.7% | 30.3% | -8.2% | - | 73.2% |
| Book value growth (YoY) | 1.2% | 159.4% | 40.8% | 11.1% | 3571.4% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$21.31B totalHospital Operations$16.14B · 75.7%
Ambulatory Care$5.17B · 24.3%
Product / service
$35.25B totalHealth Care Patient Service Excluding Physician Practices$13.94B · 39.5%
Health Care Patient Service Managed Care$9.70B · 27.5%
Health Care Patient Service$4.96B · 14.1%
Other Revenues$2.20B · 6.2%
Medicare$2.12B · 6.0%
Health Care Patient Service Medicaid$1.52B · 4.3%
Health Care Patient Service Indemnity And Other$551.00M · 1.6%
Health Care Other Sources$216.00M · 0.6%
Health Care Patient Service Selfpay$52.00M · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.38
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-General Medical & Surgical Hospitals, NEC
Comparing TENET HEALTHCARE CORP against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Mar 13, 2000 | $0.0267 |